Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting.

Clinical pharmacokinetics - 1 May 2015

Lee Kyunghoon, Woo Hye In, Bang Oh Young, On Young-Keun, Kim June Soo, Lee Soo-Youn

Abstract excerpt

BACKGROUND AND OBJECTIVES: Approximately 50% of inter-individual variation in warfarin dose requirements is attributed to the polymorphisms of cytochrome P450 (CYP) 2C9 (CYP2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) genotypes. What contributes to the remaining 50% of variation remains unclear. The aim of this study is to assess the clinical usefulness of monitoring plasma warfarin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to International Normalized Ratio

Share to Linear Models

Share to Tandem Mass Spectrometry

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 25466603
DOI: 10.1007/s40262-014-0219-1

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting.PMID 25466603Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.Semantic proximity Read ↗

Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.Semantic proximity Read ↗

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Semantic proximity Read ↗

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.Semantic proximity Read ↗

Pharmacogenetics of warfarin: current status and future challenges.Semantic proximity Read ↗

Integrated analysis of clinical and genetic factors on the interindividual variation of warfarin anticoagulation efficacy in clinical practice.Semantic proximity Read ↗

Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.